Tissue-based Genomics Augments Post-prostatectomy Risk Stratification in a Natural History Cohort of Intermediate- and High-Risk Men.
about
Performance characteristics of prostate-specific antigen density and biopsy core details to predict oncological outcome in patients with intermediate to high-risk prostate cancer underwent robot-assisted radical prostatectomy.Neuropilin-1 is upregulated in the adaptive response of prostate tumors to androgen-targeted therapies and is prognostic of metastatic progression and patient mortality.A 22 Gene-expression Assay, Decipher® (GenomeDx Biosciences) to Predict Five-year Risk of Metastatic Prostate Cancer in Men Treated with Radical ProstatectomyClinical Validation of the 2005 ISUP Gleason Grading System in a Cohort of Intermediate and High Risk Men Undergoing Radical ProstatectomyEvaluation of a genomic classifier in radical prostatectomy patients with lymph node metastasisClinically available RNA profiling tests of prostate tumors: utility and comparisonDecipher correlation patterns post prostatectomy: initial experience from 2 342 prospective patients.Decreased TSPAN1 promotes prostate cancer progression and is a marker for early biochemical recurrence after radical prostatectomy.Multidisciplinary intervention of early, lethal metastatic prostate cancer: Report from the 2015 Coffey-Holden Prostate Cancer Academy Meeting.Molecular biomarkers to guide precision medicine in localized prostate cancer.Androgen Receptor Deregulation Drives Bromodomain-Mediated Chromatin Alterations in Prostate Cancer.Validation of a Genomic Risk Classifier to Predict Prostate Cancer-specific Mortality in Men with Adverse Pathologic Features.Risk stratification of prostate cancer 2016.The very-high-risk prostate cancer: a contemporary update.Transcriptome evaluation of the relation between body mass index and prostate cancer outcomes.Genomic tests to guide prostate cancer management following diagnosis.Correlation of B7-H3 with androgen receptor, immune pathways and poor outcome in prostate cancer: an expression-based analysis.Genomic testing for localized prostate cancer: where do we go from here?Use of the cell cycle progression (CCP) score for predicting systemic disease and response to radiation of biochemical recurrence.Decipher test impacts decision making among patients considering adjuvant and salvage treatment after radical prostatectomy: Interim results from the Multicenter Prospective PRO-IMPACT study.Low PCA3 expression is a marker of poor differentiation in localized prostate tumors: exploratory analysis from 12,076 patients.Molecular heterogeneity of localized prostate cancer: more different than alike.Efficacy of post-operative radiation in a prostatectomy cohort adjusted for clinical and genomic riskAssociations of Luminal and Basal Subtyping of Prostate Cancer With Prognosis and Response to Androgen Deprivation Therapy.TOP2A and EZH2 Provide Early Detection of an Aggressive Prostate Cancer Subgroup.Tissue-Based MicroRNAs as Predictors of Biochemical Recurrence after Radical Prostatectomy: What Can We Learn from Past Studies?Gene expression signatures of neuroendocrine prostate cancer and primary small cell prostatic carcinoma.Tissue-based biomarkers in prostate cancer.MSH2 Loss in Primary Prostate Cancer.Drug development for noncastrate prostate cancer in a changed therapeutic landscape.Analytic, Preanalytic, and Clinical Validation of p53 IHC for Detection of TP53 Missense Mutation in Prostate Cancer.Digitizing omics profiles by divergence from a baseline.The Use of Biomarkers in Prostate Cancer Screening and Treatment.Men with a susceptibility to prostate cancer and the role of genetic based screening.Comprehensive Determination of Prostate Tumor ETS Gene Status in Clinical Samples Using the CLIA Decipher Assay.Development and Validation of a 28-gene Hypoxia-related Prognostic Signature for Localized Prostate Cancer.Chemotherapy and radiation for prostate cancerAdjuvant Versus Salvage Radiotherapy for Patients With Adverse Pathological Findings Following Radical Prostatectomy: A Decision AnalysisCombined Performance of Screening and Variable Selection Methods in Ultra-High Dimensional Data in Predicting Time-To-Event Outcomes
P2860
Q33827605-6CFA7B91-A707-4A23-979E-0C8366F3D53FQ33835918-60E3458F-60B0-4237-921A-7F7EF58F8B02Q35868145-55F3143D-41D6-429E-915D-A3919A2DE8A5Q35885756-35E67ED7-C10C-4183-A27B-62C175E2954BQ37070927-856451F0-4C35-45C1-8F4E-1EE8C96A93F8Q37113181-C3107026-78C6-46EB-AB78-9B6CBADEBD30Q37463713-470B5A49-FC57-430A-B018-D33B5EF591E1Q37665314-E8C9A866-F00A-49C7-BDFB-31FC9F1D186BQ38610286-EBB6935D-6A6A-4EBF-ACC6-9B75B0101F82Q38668635-BC69CF8B-A4D9-4562-99D0-25796D20AA86Q38673660-82ABDE16-D5B9-4036-B159-41F79A06630EQ38841717-E99363B4-5B39-4DC7-9B05-8F72C6E1E928Q38929868-9C393DA3-5B5B-42FC-B903-7B50AF685757Q38952181-57112D72-F046-479F-AFEB-2D1876099FD4Q38989776-AE726635-26A1-4EAB-A77F-C295894213FEQ39170943-19EDA7B7-533A-43E1-B1D3-E9811D721A91Q39227619-C7AFD8D9-E5A4-425E-A4FC-B1C47093F002Q39404903-16E83966-CF27-4648-B244-EBEA23C1CCA9Q39675735-8E8A2376-946A-451C-BB6D-F6068CC3BBCFQ41540713-DCFD094A-CB55-44E5-A936-696410988AECQ41612462-92A3A69D-DD9D-4B09-9427-C57C2E1CBC75Q42255184-A4BAFDFB-E94A-4499-BDE2-8D6B5EEF2D44Q42290038-44A3E04F-1973-49D1-89B1-5588689B7933Q42509592-985AF93E-674B-4948-9AA5-6E2F84910B36Q46838481-619A071A-A955-41F1-83B0-35F69F097E22Q47109138-8D22D808-186B-4879-9618-69EC8916F739Q47140347-60ED601F-F51C-4ACC-A913-6BCAB99D9005Q47144748-7AEA5791-4C02-438F-B37C-7F20F6BEDDA7Q47976701-CF49FB05-A19C-4295-94E5-BE3EAD791897Q48629219-3CFB7AAC-D07B-4668-B6B6-027E9B7B4B98Q51033341-CFA37D27-F65A-4BF4-9259-38995EA47E62Q52318690-AA160408-6F50-4004-94A2-3CAE996EC62DQ52689045-2381DB8D-07BD-40BB-8D85-2D9021CD03FFQ53423427-379AF60A-C6DE-455D-8FCF-4DC3B8BBF640Q54474207-18B2C045-04F1-4FF2-BDD9-5A49BD9ECE41Q55398136-831E111C-3C22-43FD-A523-175C23216307Q57112428-127172AB-E4CC-4013-A10D-946AD4C79CE7Q57153443-2D6009B5-2364-4287-9152-2A023C8EA770Q58579384-2DB79B50-76B4-4B9B-90D9-DAE1F489D472
P2860
Tissue-based Genomics Augments Post-prostatectomy Risk Stratification in a Natural History Cohort of Intermediate- and High-Risk Men.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Tissue-based Genomics Augments ...... termediate- and High-Risk Men.
@en
type
label
Tissue-based Genomics Augments ...... termediate- and High-Risk Men.
@en
prefLabel
Tissue-based Genomics Augments ...... termediate- and High-Risk Men.
@en
P2093
P50
P1433
P1476
Tissue-based Genomics Augments ...... termediate- and High-Risk Men.
@en
P2093
Christine Buerki
Elizabeth B Humphreys
George J Netto
Helen L Fedor
Lucia L Lam
Luigi Marchionni
Michael H Johnson
Sheila Faraj
Stephania M Bezerra
Stephanie Glavaris
P304
P356
10.1016/J.EURURO.2015.05.042
P407
P50
P577
2015-06-06T00:00:00Z